When added to the current standard therapy, AEOL
10150 improves survival to 100 percent.
Authority (BARDA) to develop AEOL
10150 Pulmonary Acute Radiation Syndrome.
The contract with BARDA will fully fund the development of AEOL
10150 as a treatment for radiation exposure resulting from a nuclear detonation, and puts the Company in a position to potentially file for Emergency Use Authorization as early as July 2013.
OTC: AOLS), a biopharmaceutical company developing a new class of broad spectrum catalytic antioxidant compounds that reduce oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure, today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS), has awarded Aeolus a contract for the advanced development of AEOL
10150 as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (ARS).
The Company received payment in full for one grant in support of development of AEOL
10150 as a medical countermeasure for Lung-ARS in November and approximately $92,000 as a partial payment in support of our development of AEOL
11207 as a potential treatment for Parkinson's Disease.
The Company's presentation, entitled "AEOL
10150 - A Dual Use, Broad Spectrum Medical Countermeasure Against Radiological and Chemical Threats," includes new data demonstrating that AEOL
10150 protects the lungs and improves survival in both mouse and non-human primate models of Lung ARS, as well as new data showing that the compound also protects and mitigates damage to the lungs in a rat model of chlorine gas exposure.
Reported survival advantage in non-human primate study of AEOL
11207, when orally administered, crosses the blood brain barrier, penetrates brain cells and protects brain cells that produce dopamine
We are grateful for the support the QTDP grants will provide to further our development programs for AEOL
10150 and AEOL
11207," stated John L.
The Company expects to use the net proceeds from this financing to advance the clinical development of AEOL
10150, to complete toxicity and other work necessary to file Investigational New Drug applications for at least one of its pipeline compounds, and for general administrative expenses and working capital.
The primary objective of the study was to determine if AEOL
10150 could mitigate radiation-induced lung injury and enhance survival in rhesus macaques exposed to whole thorax lung irradiation (WTLI) and administered supportive care.
Significant progress continues in our development programs for AEOL
10150 as a Medical Countermeasure (MCM) for radiation, chlorine gas and sulfur mustard gas exposure and AEOL
11207 as a potential therapy for Parkinson's disease and epilepsy," stated John L.